Kala Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
KALA
CUSIP
483119202
All holders as of
Q1 2026
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 483119202 since 12/18/2024, largest first.

Filer % of Class Filed
Oxford Finance LLC 13G 16.5% 12/3/2025
Event 11/25/2025
Baker Bros. Advisors LP 13G/A
10.0% 2/17/2026
Event 12/31/2025
LifeSci Capital LLC 13G
7.9% 1/13/2026
Event 12/30/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (7)
David E. Lazar 13D
Amended under CUSIP 483119301 on 7/2/2026
5.2% 2/6/2026
Event 1/30/2026
ADAR1 Capital Management, LLC 13G/A
4.9% 2/14/2025
Event 12/31/2024
SR One Capital Management, LLC 13D/A
4.6% 10/15/2025
Event 10/14/2025
Point72 Asset Management, L.P. 13G/A
0% 11/14/2025
Event 9/30/2025
Cormorant Asset Management, LP 13G/A
0% 11/14/2025
Event 9/30/2025
Millennium Management LLC 13G/A
0% 5/12/2025
Event 3/31/2025
Perceptive Advisors LLC 13G/A
0% 11/14/2025
Event 9/30/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q1 27 1.70 M $294 k
2025 Q4 29 2.84 M $1.58 M
2025 Q3 23 1.75 M $2.69 M
2025 Q2 29 3.64 M $17.3 M
2025 Q1 28 4.14 M $23.7 M
2024 Q4 33 3.46 M $24.0 M
2024 Q3 28 2.12 M $12.1 M
2024 Q2 31 2.09 M $14.8 M
2024 Q1 32 620 k $4.90 M
2023 Q4 27 528 k $3.69 M
2023 Q3 26 514 k $4.57 M
2023 Q2 28 381 k $5.56 M
2023 Q1 25 319 k $4.81 M
2022 Q4 31 334 k $12.8 M
2022 Q3 1 90.5 k $20.0 k